Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 19/20 | 0.72 |
| ▸ | KDM6B | O15054 | 1/20 | 0.57 |
| ▸ | KDM4A | O75164 | 1/20 | 0.57 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.57 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.57 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.57 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.57 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004451 | 0.87 | PLA2G7 (0.60) | PLA2G7 | |
| SCHEMBL7005768 | 0.84 | PLA2G7 (1.00) | PLA2G7 | |
| SCHEMBL7009888 | 0.83 | PLA2G7 (0.69) | PLA2G7KDM6BKDM4AKDM4DKDM3B | |
| SCHEMBL7012270 | 0.83 | PLA2G7 (1.00) | PLA2G7 | |
| SCHEMBL7004753 | 0.83 | PLA2G7 (1.00) | PLA2G7 | |
| SCHEMBL7011572 | 0.83 | PLA2G7 (1.00) | PLA2G7 | |
| SCHEMBL7010251 | 0.83 | PLA2G7 (1.00) | PLA2G7 | |
| SCHEMBL7005639 | 0.81 | PLA2G7 (1.00) | PLA2G7 | |
| SCHEMBL7009108 | 0.81 | PLA2G7 (1.00) | PLA2G7 | |
| SCHEMBL7005854 | 0.81 | PLA2G7 (1.00) | PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028955-B1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 2003-07-16 | — | — | EP | claimed |
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | HICKEY DEIRDRE MARY BERNADETTE (GB) | 2002-08-29 | — | — | US | disclosed |
| US-6417192-B1 | DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | PLA2G7, PLA2G1B, PLA2G4C | PLA2G7 1/4885KDM6B 2705/4885KDM4A 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.